KURA Kura Oncology, Inc.
Listings ·
The plan was amended by the board on October 15, 2025 and is filed as an exhibit. It is built around Nasdaq's inducement-grant exemption from shareholder approval.
We have not published a story on Kura Oncology yet. When there is news, it will appear here.
Kura Oncology is a company whose commercial focus in this filing is KOMZIFTI (ziftomenib), which it is commercializing in the United States. The filing states that the company's ability to generate meaningful revenue or achieve profitability depends on successfully commercializing KOMZIFTI in the United States and on expanding ziftomenib's indications of use and market opportunity. It also flags risks that physicians, patients, third-party payors and the wider medical community may not accept KOMZIFTI to the degree needed for commercial success, and that the market opportunity could prove smaller than the company believes. The company notes that post-approval results for KOMZIFTI in larger numbers of patients, broader populations or real world clinical practice may not be consistent with its clinical trial results. Its risk disclosures also cover the success of competing drugs and the timing and ability to obtain and maintain regulatory approval of its existing product candidates. The filing describes ongoing research and development activities, clinical trials and preclinical studies for further candidates.
| Product or program | What it is | Stage |
|---|---|---|
| KOMZIFTI (ziftomenib) | Ziftomenib product commercialized in the United States | Commercializing in the United States |
| Line | FY2025 | FY2024 |
|---|---|---|
| Revenue | $67.5 million | $53.9 million |
| Research and development | $251.1 million | $170.0 million |
| Net income (loss) | -$278.7 million | -$174.0 million |
| Cash from operations | -$64.1 million | $134.3 million |
| Cash and equivalents | $149.1 million | $224.5 million |
| Short-term investments | $518.1 million | $502.9 million |
Kura Oncology, Inc. trades under the ticker KURA on NASDAQ.
Kura Oncology, Inc. is listed on NASDAQ. Our directory also records these other listings: GETTEX:KUR; LS:A143UH; LSX:A143UH.
The SEC Central Index Key (CIK) for Kura Oncology, Inc. is 1422143. Its filings are on SEC EDGAR.
88,960,619 shares as of 2026-08-07, per the cover page of its 10-Q filed 2026-08-12.
Our directory records Kura Oncology, Inc. under United States.
Our directory classifies Kura Oncology, Inc. as: Biotechnology. This is a directory classification, not a description of the pipeline.
The ISIN recorded for Kura Oncology, Inc. is US50127T1097.
aibio.space lists Kura Oncology, Inc. among 2,820 public biotech companies and publishes its news here as stories appear.
SEC records list its state or country of incorporation as DE.
Kura Oncology is a company whose commercial focus in this filing is KOMZIFTI (ziftomenib), which it is commercializing in the United States. The filing states that the company's ability to generate meaningful revenue or achieve profitability depends on successfully commercializing KOMZIFTI in the United States and on expanding ziftomenib's indications of use and market opportunity.
KOMZIFTI (ziftomenib): Ziftomenib product commercialized in the United States Stage: Commercializing in the United States.
$67.5 million for the fiscal year ended Dec 31, 2025, as reported to the SEC.
Kura Oncology, Inc. reported a net loss of $278.7 million for the fiscal year ended Dec 31, 2025, and used $64.1 million of cash in operations, per its annual report to the SEC.
$251.1 million in the fiscal year ended Dec 31, 2025, per its annual report.
$519.0 million in cash and short-term investments at Jun 30, 2026, per its 10-Q.
Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction
aibio